Scientific technology by Rarecells

Isolation by Size of Epithelial Tumor Cells - a revolutionary diagnostic method

Company Profile

RARECELLS SAS was formed In December 2009 by Patrizia Paterlini Brechot, Professor of Cell Biology and Oncology , in order to commercialize the result of her research: the patented ISET (Isolation by Size of Epithelial/Throphoblastic Tumor cells) device to isolate Circulating Rare Cells in blood.

ISET forms the base platform for clinical applications in cancer, pre-natal diagnosis and other emerging fields. It is poised to be the technology of choice in detection of CTCs because it addresses the key problems of reliable tumor cell detection: sensitivity and specificity. In addition, an ISET-like system has been developed for the isolation of Circulating Fetal Cells (CFC) from maternal blood (ISET-PND) to replace amniocentesis by a non invasive genetic test for Trisomy-21, Cystic Fibrosis and other genetic disorder (ISET-PND test).

Other emerging fields include Stem Cells, cardiology...

Rarecells USA:
RARECELLS US Inc. was formed in July 2010, in order to establish RARECELLS on the US Market. This company got awarded a federal grant in October, 2010 under the Qualifying Therapeutic Discovery Project Program.

Rarecells has established a partnership in Nice to develop a platform for Cytopathological and molecular analysis of CTC.

  • About the founder

    Patrizia Paterlini

    MD, PhD

    Professor of Cell biology and Oncology , Director at INSERM, Patrizia Paterlini-Brechot is the founder of Rarecells SAS and Rarecells USA, Inc. In addition to fundamental research studies early in her career, she focused on applied research, targeting the domains of predictive oncology and prenatal diagnosis. In 2000, her research led to the discovery and development of the now patented ISET technique for isolation and characterization of circulating tumor and fetal cells permitting predictive oncology and non invasive prenatal diagnosis. Dr Paterlini-Brechot oversees the continuing development of the ISET techniques. Her work has earned her numerous awards and led to high level publications.

  • Scientific Advisory

    Dr. Hood Leroy

    M.D., Johns Hopkins School of Medicine, 1964 Ph.D., Biochemistry, California Institute of Technology, 1968

    Dr. Hood's research has focused on the study of molecular immunology, biotechnology, and genomics.  He won the 2003 Lemelson-MIT Prize for inventing "four instruments that have unlocked much of the mystery of human biology" by helping decode the genome. His inventions include the DNA sequencer that has revolutionized genomics and contributed to the successful mapping of the human genome.[learn more]

    Joe Leigh Simpson

    MD - Chair and Professor

    Professor of Obstetrics and Gynecology, Professor of Human and Molecular Genetics , Dr Simpson is the founding Chair at Florida International University Miami, and has served as Chair and Professor in numerous universities in the USA.  Besides, he has played leadership roles in many professional organizations. His research encompasses many areas of genetic prenatal diagnosis and reproductive genetics.[learn more]

    Frank Anthony Greco


    Dr. Tony Greco is board certified in Medical Oncology and Internal Medicine. He has been with Tennessee Oncology since 1993 and practicing medicine since 1976. Dr. Greco specializes in cancers of unknown primary, lung cancer, and germ cell tumors. Dr. Greco holds memberships in the American Society of Clinical Oncology and the Southern Association of Oncology. [learn more]

    Jean-Yves Blay

    MD, PhD

    Dr. Jean-Yves Blay is Professor of Medicine at the Université Claude Bernard in Lyon, France, and the Scientific Director of the Canceropole Lyon Rhône Alpes, a network of more than 1500 researchers and physicians working in the field of cancer . He is President of the Executive Committee of the EORTC (European Organization for the Research and Treatment of Cancer), Chairman of the French Sarcoma Group, and Director in the Conticanet Network (, a Network of excellence funded by the 6th FrameWork Program of the European Commission.[learn more]